STOCK TITAN

OBSV - OBSV STOCK NEWS

Welcome to our dedicated page for OBSV news (Ticker: OBSV), a resource for investors and traders seeking the latest updates and insights on OBSV stock.

ObsEva SA is a biopharmaceutical company based in Plan-les-Ouates, Switzerland, specializing in the development and commercialization of novel therapies to enhance women's reproductive and pregnancy health. Founded in 2012, ObsEva is dedicated to addressing unmet needs in reproductive medicine by focusing on innovative treatments that aim to improve fertility outcomes and manage preterm labor.

Currently, ObsEva is involved in several key projects, including their lead product linzagolix, an oral GnRH antagonist designed to treat uterine fibroids and endometriosis. This medication aims to offer significant benefits over existing treatments by providing symptom relief with fewer side effects.

ObsEva's approach is underscored by a robust pipeline and strategic partnerships with leading healthcare organizations. Financially, the company continues to navigate its path with a focus on securing funding to propel its clinical trials and regulatory submissions. Recently, ObsEva has made significant strides with positive results from their Phase 3 trials for linzagolix, putting them on track for potential market approval.

ObsEva's commitment to innovation and patient health is reflected through its continuous efforts in research and development, making significant progress in areas with high medical needs. The company's forward-looking strategy is built on scientific rigor, collaborative partnerships, and a deep understanding of women's health issues.

For more information, please contact:
General inquiries: contact@obseva.ch
Investor relations: IR@obseva.ch

ObsEva SA
Chemin des Aulx 12,
1228 Plan-les-Ouates,
Switzerland

Rhea-AI Summary
ObsEva SA has announced the appointment of Fabien de Ladonchamps as the new Chief Executive Officer, effective May 1, 2023. He succeeds Will Brown, who previously held the position of Interim CEO and CFO. Mr. Brown will serve as a strategic advisor for the next six months. Fabien de Ladonchamps has 25 years of experience in finance and administrative roles in the biotech industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

ObsEva SA, a biopharmaceutical company focused on women's health, announced a transition for its common shares to trade under a new International Securities Identification Number (ISIN) starting April 25, 2023. This change follows the delisting of ObsEva's shares from the Nasdaq Capital Market effective March 23, 2023, and subsequent deregistration from the SEC.

The common shares will no longer be eligible for settlement through The Depository Trust Company (DTC) and will be managed by SIX SIS AG, the central securities depositary for the SIX Swiss Exchange. As of April 24, 2023, the old ISIN and CUSIP will be canceled, with trading commencing under the new ISIN CH1260041939.

Shareholders with custodians connected to SIX SIS will receive the new ISIN shares automatically, while others must arrange accordingly by the deadline.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

ObsEva has released its U.S. Annual Report on Form 10-K for the fiscal year 2022, disclosing key financial results as of year-end 2022. The report can be accessed on its website. The company, focusing on women's reproductive health and pregnancy, is traded on the SIX Swiss Exchange under the ticker OBSN and on the OTC Pink Market as OBSVF. Additionally, ObsEva plans to publish its Swiss Annual Report to Shareholders, including IFRS results, in the week of April 24, 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

ObsEva SA announced its scheduled delisting from Nasdaq starting March 23, 2023, as it failed to maintain a minimum bid price of $1.00 per share for 30 consecutive days. The company received a notification on March 14, 2023, regarding this delisting, and it plans to file a Form 25-NSE with the SEC to deregister its securities under the U.S. Securities Exchange Act. Although the Nasdaq listing will cease, ObsEva intends to maintain its listing on the SIX Swiss Exchange under the ticker symbol “OBSN”. This transition is expected to lower its general and administrative costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

ObsEva SA (NASDAQ: OBSV; SIX: OBSN) announced leadership changes on March 13, 2023. Ernest Loumaye has been appointed as Interim Chairman after Annette Clancy's resignation, serving until the 2023 Annual General Meeting. Fabien de Ladonchamps is set to become the new Chief Executive Officer on or about May 1, 2023, bringing 25 years of biotech experience. His prior roles at ObsEva helped raise over $110 million through equity financings. The company emphasizes a focus on women's health and reproductive therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

ObsEva SA (NASDAQ: OBSV) announced a strategic reorganization on February 24, 2023, focusing operations in Switzerland to conserve cash and prioritize the development of nolasiban, aimed at improving IVF success rates. The reorganization includes downsizing its US executive team and proposing a reduced Board of Directors. Notably, ObsEva expects to be delisted from Nasdaq due to non-compliance with listing rules and plans to deregister from the SEC, while maintaining its listing on the SIX Swiss Exchange. The changes are projected to result in annual savings of approximately $3.5 million. Furthermore, ObsEva extinguished $6.5 million in convertible debt.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

ObsEva SA announced that a Geneva court has approved the withdrawal of its moratorium, confirming the company is no longer over-indebted. This decision follows the sale of rights to Ebopiprant to XOMA Corporation for $15 million, with potential milestone payments up to $98 million. ObsEva is now refocusing on nolasiban, aimed at improving in vitro fertilization success rates, retaining worldwide commercial rights except for China, where trials are set to begin with Yuyuan BioScience.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

ObsEva SA provided an update on its compliance with Nasdaq's minimum stockholders’ equity requirement. Following a previous non-compliance notification, the company reported an increase in stockholders' equity to approximately $11.4 million as of November 30, 2022, due to the sale of rights to Ebopiprant to XOMA Corporation for $15 million, plus potential future milestones totaling up to $98 million. The company has submitted a plan to Nasdaq for continued compliance and has withdrawn its moratorium with Swiss courts due to reduced debt.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

ObsEva SA announced a share capital increase, issuing 20,000,000 new shares at a price of 1/13 of a Swiss Franc each. Approved on December 8, 2022, this move aims to provide treasury shares for future fundraising and equity plans. The new shares will be fully subscribed by ObsEva USA Inc. and listed on the SIX Swiss Exchange around December 12, 2022. This capital increase comes amid ongoing challenges including potential risks related to debt obligations and compliance with Nasdaq listing rules.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is ObsEva SA's core business?

ObsEva SA specializes in developing therapies for women's reproductive and pregnancy health.

Where is ObsEva SA headquartered?

ObsEva SA is headquartered in Plan-les-Ouates, Switzerland.

What is linzagolix?

Linzagolix is an oral GnRH antagonist developed by ObsEva to treat uterine fibroids and endometriosis.

How can I contact ObsEva for general information?

You can contact ObsEva at contact@obseva.ch for general inquiries.

How can investors get in touch with ObsEva?

Investors can reach out to ObsEva at IR@obseva.ch.

What are some recent achievements of ObsEva?

ObsEva has reported positive results from their Phase 3 trials for linzagolix, positioning them for potential market approval.

Does ObsEva have any strategic partnerships?

Yes, ObsEva collaborates with leading healthcare organizations to advance their research and development efforts.

What is the focus of ObsEva's research and development?

ObsEva focuses on innovative treatments to improve fertility outcomes and manage preterm labor.

How does linzagolix differ from existing treatments?

Linzagolix aims to provide symptom relief for uterine fibroids and endometriosis with fewer side effects compared to existing treatments.

What is ObsEva's commitment to women's health?

ObsEva is dedicated to addressing unmet needs in reproductive medicine through rigorous scientific research and innovative therapies.

OBSV

Nasdaq:OBSV

OBSV Rankings

OBSV Stock Data

Medicinal and Botanical Manufacturing
Manufacturing
Link
Switzerland
Plan Les Ouates